Over-expression of c-erbB-2 correlates with nuclear morphometry and prognosis in breast carcinoma in Asian women

Pathology

Volumn 38, Issue 6, 2006, Pages 528-533

  Selvarajan, Sathiyamoorthy ^a   Wong, Ka Yan ^a   Khoo, Kei Siong ^b   Bay, Boon Huat ^c   Tan, Puay Hoon ^a,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

c erbB 2 immunohistochemistry; Invasive breast carcinoma; Nuclear morphometry; Overall survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASIAN; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROMORPHOLOGY; OVERALL SURVIVAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; BREAST TUMOR; CELL NUCLEUS; ETHNOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL NUCLEUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247170476     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020601024060     Document Type: Article

References (31)

1. Marx D, Schauer A, Reiche C, et al. C-erbB2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 1990; 116: 15-20.
2. Sjogren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462-9.
3. Yokota T, Imamura M, Teshima S, et al. C-erbB-2, p53 protein expression and steroid hormone receptors in breast carcinomas: an immunohistochemical study. Anticancer Res 1999; 19: 4007-12.
4. Tsutsui S, Ohno S, Murakami S, et al. Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. Am J Surg 2003; 185: 165-7.
5. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
6. Nahta R, Esteva F. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 2003; 9: 5078-84.
7. Mittra I, Redkar AA, Badwe RA. Prognosis of breast cancer: evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes. J Surg Oncol 1995; 60: 106-11.
8. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
9. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-56.
10. Arnould L, Fargeot P, Bonneterre J, et al. Epirubicin dose response effect in node positive breast cancer patients is independent of HER2 overexpression: 10-year retrospective analysis of French Adjuvant Study Group 05 trial. Breast Cancer Res Treat 2003; 76: A538.
11. Sloane JP, Anderson TJ, Blamey RW, et al. Pathology reporting in breast cancer screening. 2nd ed. National Coordinating Group for Breast Screening Pathology. Sheffield: NHSBSP Publications, 1995; no 3: 19-21.
12. Fleming ID, Cooper JS, Henson DE, et al., editors. AJCC: Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.
13. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-78.
14. Hoff ER, Tubbs RR, Myles JL, et al. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol 2002; 117: 916-21.
15. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421: 756-60.
16. Konigshoff M, Wilhelm J, Bohle RM, et al. HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. Clin Chem 2003; 49: 219-29.
17. Tsuda H, Iwaya K, Fukutomi T, et al. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 1993; 84: 394-401.
18. Ferrero-Pous M, Hacene K, Bouchet C, et al. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 2000; 6: 4745-54.
19. Zhang GJ, Tsuda H, Adachi I, et al. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. Jpn J Clin Oncol 1997; 27: 371-7.
20. Tsai KB, Hou MF, Lin HJ, et al. Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer. Kaohsiung J Med Sci 2001; 17: 64-76.
21. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49: 2087-90.
22. Huang J, Bay BH, Tan PH. Nuclear morphometry and glutathione S-transferase π expression in breast cancer. Oncol Rep 2000; 7: 609-13.
23. Ikeguchi M, Sato N, Hirooka Y, et al. Computerized nuclear morphometry of hepatocellular carcinoma and its relation to proliferative activity. J Surg Oncol 1998; 68: 225-30.
24. Kronqvist P, Kuopio T, Collan Y. Morphometric grading of breast cancer: thresholds for tubular differentiation. Br J Cancer 2000; 82: 1656-61.
25. Tan PH, Goh BB, Chiang G, et al. Correlation of nuclear morphometry with pathologic parameters in ductal carcinoma in situ of the breast. Mod Pathol 2001; 14: 937-41.
26. Giardina C, Serio G, Lepore G, et al. Pure ductal carcinoma in situ and in situ component of ductal invasive carcinoma of the breast. A preliminary morphometric study. J Exp Clin Cancer Res 2003; 22: 279-88.
27. Poller DN, Galea M, Pearson D, et al. Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. Breast Cancer Res Treat 1991; 20: 3-10.
28. Suo Z, Yang H, Mei Q, et al. Type 1 protein tyrosine kinases in Chinese breast carcinomas: a clinicopathologic study. Int J Surg Pathol 2001; 9: 177-87.
29. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354: 2103-11.
30. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001; 61: 8452-88.
31. Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in extrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998; 4: 7-12.